Free Trial

Standard BioTools Inc. (NASDAQ:LAB) Shares Acquired by State Street Corp

Standard BioTools logo with Medical background

State Street Corp lifted its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 26.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,495,136 shares of the company's stock after acquiring an additional 1,157,984 shares during the quarter. State Street Corp owned 1.48% of Standard BioTools worth $10,606,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Bank of New York Mellon Corp increased its stake in shares of Standard BioTools by 1,019.8% in the second quarter. Bank of New York Mellon Corp now owns 980,983 shares of the company's stock worth $1,736,000 after buying an additional 893,383 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Standard BioTools by 184.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,330 shares of the company's stock worth $89,000 after purchasing an additional 32,640 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Standard BioTools in the 2nd quarter valued at about $57,000. Rhumbline Advisers lifted its position in shares of Standard BioTools by 3,691.1% during the second quarter. Rhumbline Advisers now owns 407,467 shares of the company's stock worth $721,000 after purchasing an additional 396,719 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in Standard BioTools by 27.3% in the second quarter. Victory Capital Management Inc. now owns 46,967 shares of the company's stock worth $83,000 after purchasing an additional 10,067 shares in the last quarter. Institutional investors and hedge funds own 53.74% of the company's stock.

Standard BioTools Trading Down 4.2 %

Standard BioTools stock traded down $0.08 during mid-day trading on Friday, reaching $1.82. The company's stock had a trading volume of 1,183,203 shares, compared to its average volume of 2,374,865. The firm has a market cap of $677.51 million, a price-to-earnings ratio of -2.56 and a beta of 1.61. Standard BioTools Inc. has a twelve month low of $1.21 and a twelve month high of $3.04. The business has a 50 day moving average price of $1.87 and a 200-day moving average price of $1.92.

Wall Street Analyst Weigh In

Separately, TD Cowen cut their price objective on Standard BioTools from $2.75 to $2.50 and set a "buy" rating on the stock in a research note on Thursday, October 31st.

Check Out Our Latest Stock Analysis on Standard BioTools

Standard BioTools Company Profile

(Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

Featured Articles

Institutional Ownership by Quarter for Standard BioTools (NASDAQ:LAB)

Should You Invest $1,000 in Standard BioTools Right Now?

Before you consider Standard BioTools, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.

While Standard BioTools currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines